PTC Therapeutics is focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases. The lead asset, sepiapterin, targets adult and paediatric patients with phenylketonuria and is in Phase III development. PTC Therapeutics listed on NASDAQ in 2013.